Weekly Research Analysts’ Ratings Updates for Intuitive Surgical (ISRG)

Several brokerages have updated their recommendations and price targets on shares of Intuitive Surgical (NASDAQ: ISRG) in the last few weeks:

  • 1/10/2019 – Intuitive Surgical had its “sell” rating reaffirmed by analysts at Northland Securities. They now have a $375.00 price target on the stock. They wrote, “We are tweaking our models accordingly, and are introducing our FY20 numbers. Key Points Instrument & Accessory revs @ $539M vs. our estimate @ $535M. Systems revs @ $340M vs. our estimate @ $327M.””
  • 1/10/2019 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $541.00 price target on the stock. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time, courtesy of strong exposure to robotics & medical mechatronics. The company’s robotic platform –  da Vinci System – recorded solid growth in recent times. This is led by strong performance in U.S. general surgery procedures and global urologic procedures. Management expects strong contributions from da Vinci in 2019 as well. Commencement of da Vinci sale in Taiwan also adds to the positives. Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company. “
  • 1/2/2019 – Intuitive Surgical was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 1/2/2019 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. Strong prospects in the company’s robotic platform – da Vinci System – is a major positive. Notably, da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 1/2/2019 – Intuitive Surgical had its price target lowered by analysts at Citigroup Inc from $601.00 to $560.00. They now have a “buy” rating on the stock.
  • 12/19/2018 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $540.00 price target on the stock. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. Strong prospects in the company’s robotic platform – da Vinci System – is a major positive. Notably, da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 12/13/2018 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. Strong prospects in the company’s robotic platform – da Vinci System – is a major positive. Notably, da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 12/12/2018 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $569.00 price target on the stock. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. Strong prospects in the company’s robotic platform – da Vinci System – is a major positive. Notably, da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 12/7/2018 – Intuitive Surgical was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 12/6/2018 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intuitive Surgical expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company. On the brighter side, strong prospects in the company’s robotic platform – da Vinci System – is a positive. da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. The company outperformed the industry in a year’s time. “
  • 12/5/2018 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $615.00 price target on the stock. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. The company’s robotic platform – da Vinci procedures –recorded solid growth in recent times. Higher worldwide da Vinci procedures led by growth in U.S. general surgery procedures and global urologic procedures is a positive. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 11/29/2018 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. The company’s robotic platform – da Vinci procedures –recorded solid growth in recent times. Higher worldwide da Vinci procedures led by growth in U.S. general surgery procedures and global urologic procedures is a positive. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 11/29/2018 – Intuitive Surgical had its price target lowered by analysts at Citigroup Inc from $606.00 to $601.00. They now have a “buy” rating on the stock.
  • 11/27/2018 – Intuitive Surgical is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $540.00 price target on the stock.
  • 11/22/2018 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $543.00 price target on the stock. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. The company’s robotic platform – da Vinci procedures –recorded solid growth in recent times. Higher worldwide da Vinci procedures led by growth in U.S. general surgery procedures and global urologic procedures is a positive. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 11/21/2018 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. The company’s robotic platform – da Vinci procedures –recorded solid growth in recent times. Higher worldwide da Vinci procedures led by growth in U.S. general surgery procedures and global urologic procedures is a positive. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”
  • 11/15/2018 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $564.00 price target on the stock. According to Zacks, “Intuitive Surgical outperformed the industry in a year’s time. The company’s robotic platform – da Vinci procedures –recorded solid growth in recent times. Higher worldwide da Vinci procedures led by growth in U.S. general surgery procedures and global urologic procedures is a positive. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.”

NASDAQ ISRG opened at $505.32 on Monday. Intuitive Surgical, Inc. has a 1 year low of $380.00 and a 1 year high of $581.12. The firm has a market capitalization of $59.05 billion, a P/E ratio of 70.28, a PEG ratio of 3.44 and a beta of 1.07.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 18th. The medical equipment provider reported $2.83 EPS for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.17. Intuitive Surgical had a return on equity of 18.79% and a net margin of 22.31%. The firm had revenue of $920.90 million for the quarter, compared to analysts’ expectations of $916.22 million. During the same period last year, the firm earned $2.77 EPS. The company’s quarterly revenue was up 14.0% on a year-over-year basis. Research analysts predict that Intuitive Surgical, Inc. will post 9.54 earnings per share for the current year.

In related news, EVP David J. Rosa sold 32,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 23rd. The shares were sold at an average price of $500.86, for a total transaction of $16,277,950.00. Following the transaction, the executive vice president now owns 44,208 shares of the company’s stock, valued at $22,142,018.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jamie Samath sold 227 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $541.86, for a total transaction of $123,002.22. Following the transaction, the vice president now directly owns 138 shares in the company, valued at approximately $74,776.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,491 shares of company stock valued at $37,767,784. Insiders own 2.20% of the company’s stock.

Large investors have recently modified their holdings of the stock. FMR LLC lifted its stake in Intuitive Surgical by 19.2% in the second quarter. FMR LLC now owns 6,629,648 shares of the medical equipment provider’s stock valued at $3,172,155,000 after acquiring an additional 1,068,107 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Intuitive Surgical by 2.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,229 shares of the medical equipment provider’s stock worth $2,022,000 after buying an additional 117 shares in the last quarter. Raymond James & Associates lifted its position in Intuitive Surgical by 23.8% during the 2nd quarter. Raymond James & Associates now owns 31,778 shares of the medical equipment provider’s stock worth $15,205,000 after buying an additional 6,111 shares in the last quarter. Voya Investment Management LLC lifted its position in Intuitive Surgical by 3.6% during the 2nd quarter. Voya Investment Management LLC now owns 42,362 shares of the medical equipment provider’s stock valued at $20,269,000 after purchasing an additional 1,491 shares during the period. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Intuitive Surgical by 85.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,661 shares of the medical equipment provider’s stock valued at $1,752,000 after acquiring an additional 1,685 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Intuitive Surgical, Inc designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company's da Vinci surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports.

Read More: Institutional Investors

Receive News & Ratings for Intuitive Surgical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply